HALO · CIK 1159036
What Halozyme Therapeutics, Inc. told the SEC could break it.
Halozyme's revenue, which comes largely from royalties on partners' ENHANZE-enabled drugs, is heavily concentrated in a few relationships: one partner was 41% of total revenue in 2025, the top three (Janssen, Roche and argenx) about 74%, and 69% of receivables was due from those three. That partner-royalty stream is exposed to drug-pricing reform — the Inflation Reduction Act's Medicare price negotiation, single-source drug rules and importation proposals could cut access to and revenue from those products, lowering Halozyme's royalties. It also relies on third-party contract manufacturers, some of them its single source, for the raw materials and finished products of certain partnered and proprietary products, creating supply-interruption risk.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- one partner = 41% of revenue; top three = 74% (Janssen, Roche, argenx)high
Halozyme's revenue is heavily concentrated in a few ENHANZE partners — Partner A was 41% of total revenue, Partner B 17% and Partner C 16% in 2025 — and 69% of accounts receivable was due from Janssen, Roche and argenx.
“The following table indicates the percentage of total revenues in excess of 10% with any single customer: Year Ended December 31, 2025 2024 2023 Partner A 41 % 41 % 44 % Partner B 17 % 17 % 19 % Partner C 16 % 9 % 7 % Partner D 6 % 8 % 10 %”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug price negotiation threatening partner products' royaltiesmedium
The Inflation Reduction Act's Medicare drug-price negotiation (and related single-source drug rules / drug-importation proposals) could reduce access to and revenue from Halozyme's partners' ENHANZE-enabled products, lowering Halozyme's royalty streams.
“Legislative proposals have been introduced that, if enacted and implemented, could affect access to and revenue from our partners' products, allow the federal government to engage in price negotiations on certain drugs, and allow importation of prescription medication from Canada or other countries.”
Sole-source dependency
- single-source contract manufacturers for certain product materialsmedium
Halozyme relies on third-party CMOs — some of which are its single source — for the raw materials, components and finished products of certain of its partnered and proprietary products, creating supply-interruption risk.
“We rely on a number of third parties in our supply chain for the supply and manufacture of our partnered and proprietary products, and the availability of such products depends upon our ability to procure the raw materials, components, packaging materials and finished products from these third parties, some of which are currently our single source for the materials necessary for certain of our products.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Approximately 69 % of the accounts receivable balance as of December 31, 2025 represents amounts due from Janssen, Roche and argenx.”
Cited →“Approximately 69 % of the accounts receivable balance as of December 31, 2025 represents amounts due from Janssen, Roche and argenx.”
Cited →Roche
“Approximately 69 % of the accounts receivable balance as of December 31, 2025 represents amounts due from Janssen, Roche and argenx.”
Cited →
Its suppliers
Catalent Indiana LLC
“We have entered into supply agreements with numerous third-party suppliers. For example, we have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (“Avid”) and Catalent Indiana LLC (“Catalent”) to prod”
Cited →Avid Bioservices, Inc.
“We have entered into supply agreements with numerous third-party suppliers. For example, we have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (“Avid”) and Catalent Indiana LLC (“Catalent”) to prod”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch